Hematology
Starting from
$3,000
Up to $80,000 depending on centre
Typical duration
14–60 days
Including pre-operative work-up
Partner hospitals
22
Vetted for outcome data & accreditation
Content reviewed for medical accuracy by: Dr. Rodina Ainasoa · Medical Content Writer & Health Communications
Therapeutic use of stem cells — haematopoietic, mesenchymal, or induced pluripotent — to repair, regenerate, or replace damaged tissue in blood disorders, degenerative conditions, and select autoimmune diseases.
Your case is matched to a centre on the basis of clinical outcome data, not marketing. We coordinate every step — from pre-operative work-up to post-treatment follow-up — with a dedicated care coordinator.
Stem Cell Therapy
Coordinated from
or message us on WhatsApp
No commitment required. Your data is never shared with third parties.
Mesenchymal stem cell (MSC) therapy for orthopaedic and degenerative joint conditions uses either the patient's own cells or cells sourced from a donor. Which sourcing method, if either, is appropriate for a given condition is a decision for a qualified specialist, based on published evidence for that specific indication — not a general assumption that stem cells help every condition, per the ISSCR (International Society for Stem Cell Research) Patient Handbook.
| Parameter | Autologous (patient's own cells) | Allogeneic (donor-derived cells) |
|---|---|---|
| Cell source | Cells (commonly mesenchymal stem cells) are harvested from the patient's own bone marrow, fat tissue, or umbilical cord tissue collected at birth, then processed before use, per Mayo Clinic and Cleveland Clinic. | Cells are sourced from a donor and expanded in a laboratory; this route depends heavily on the manufacturing standard and regulatory approval of the specific product used, per ISSCR guidance. |
| Immune rejection risk | Lower theoretical risk of immune rejection, since the cells originate from the patient's own body. | A donor-derived product carries a distinct immune-response profile that depends on the specific manufacturing process; this should be evaluated by the treating specialist rather than assumed to be risk-free, per ISSCR guidance. |
| Regulatory status | Regulatory oversight varies significantly by country and by how minimally the cells are processed; the FDA has repeatedly warned that many autologous cell products marketed for orthopaedic or degenerative conditions are not FDA-approved. | Donor-derived cell products require even more rigorous manufacturing and safety oversight; the FDA has taken enforcement action against clinics marketing unapproved donor-derived stem cell products. |
| Strength of clinical evidence (knee osteoarthritis, as an example indication) | Systematic reviews of autologous MSC injection for knee osteoarthritis report improvements in pain and function versus baseline, but the certainty of evidence is rated low to very low due to small studies, high heterogeneity, and limited long-term controlled trials, per peer-reviewed systematic reviews. | Evidence for donor-derived MSC products in joint conditions is comparatively less mature than for autologous approaches and varies widely by product and study, per peer-reviewed literature. |
| What to verify before proceeding | Ask specifically what published clinical evidence exists for your exact condition, and confirm the treating centre's regulatory standing for the product used, per ISSCR patient guidance. | The same verification applies, with particular attention to the donor product's manufacturing and regulatory documentation, per ISSCR patient guidance. |
The description below outlines the general process for mesenchymal stem cell therapy for orthopaedic/degenerative joint conditions. The specific steps, cell source, and whether the therapy is appropriate at all depend on your diagnosis and the published evidence for your specific condition, as confirmed by your treating specialist.
Evaluation and cell sourcing
A specialist reviews the diagnosis, imaging, and prior treatment history to assess whether published evidence supports MSC therapy for the specific condition; if proceeding, cells are either harvested from the patient (bone marrow or fat tissue) or sourced from an approved donor-derived product, per Mayo Clinic and Cleveland Clinic.
Laboratory processing and preparation
Collected or sourced cells are processed, concentrated, and quality-checked in a laboratory before administration; the manufacturing standard used here is one of the key factors distinguishing regulated care from unregulated clinics, per ISSCR guidance.
Administration
Prepared cells are administered by injection into the target joint or tissue, typically under imaging guidance for accurate placement; this is a needle-based procedure, not a robotic surgical procedure, per Cleveland Clinic and published orthopaedic literature.
Monitoring and follow-up
Patients are monitored for immediate reactions after administration and followed up over subsequent weeks and months to assess response; because evidence quality varies by condition, follow-up should include objective assessment of the specific outcome relevant to that diagnosis, per peer-reviewed literature.
Mild soreness, swelling, or transient fever at the injection site is commonly reported and typically resolves quickly; this is the most consistently documented safety finding across published studies, per peer-reviewed systematic reviews.
Most patients resume light daily activity within days; any activity restrictions are set by the treating specialist based on the specific joint and condition treated.
Where a treatment response occurs, published studies of MSC therapy for knee osteoarthritis report improvements in pain and function typically assessed from this point onward through 24 months of follow-up; individual response is not guaranteed, per peer-reviewed systematic reviews.
Longer-term outcome data remains an active area of research with substantial study-to-study variability; patients should discuss realistic, evidence-based expectations for their specific condition with their treating specialist rather than assuming a fixed outcome timeline, per ISSCR guidance.
Source: ISSCR (International Society for Stem Cell Research) Patient Handbook; Mayo Clinic; Cleveland Clinic; peer-reviewed systematic reviews of MSC therapy for knee osteoarthritis. Individual recovery and results vary and are not guaranteed.
Known Risks & Limitations
Source: ISSCR (International Society for Stem Cell Research) Patient Handbook; FDA patient and consumer warnings on unapproved stem cell products; peer-reviewed systematic reviews. No procedure is without risk, and evidence for this treatment category varies significantly by condition; your treating specialist will review your individual case.
Remote clinical review
Share your diagnosis, imaging, and prior treatment history. Our coordination team forwards your case to a specialist for an initial assessment of whether published evidence supports stem cell therapy for your specific condition.
Evidence and regulatory verification
Before any centre is proposed, we verify its regulatory standing and the published clinical evidence base for the specific product and indication — consistent with ISSCR patient-safety guidance on avoiding unregulated 'stem cell tourism' clinics.
Clinic matching and estimate
A consolidated cost estimate covering evaluation, cell sourcing or processing, the administration procedure, and follow-up monitoring is issued before you travel.
Treatment and monitoring
Travel, the administration procedure, and immediate post-procedure monitoring are coordinated with your care team throughout.
Continuity of care post-return
A treatment summary and follow-up schedule are shared with your home specialist before you travel home, with remote coordination available for ongoing monitoring and any questions that arise.
Average coordinated costs across our partner centres. Final pricing depends on clinical complexity and chosen hospital.
| Country | Avg. cost | vs. cheapest |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $4,600 | —chevron_right |
🇹🇷 Turkey Istanbul | $20,000 | +335%chevron_right |
🇹🇭 Thailand Bangkok · Phuket · Chiang Mai | $25,000 | +443%chevron_right |
Costs are indicative estimates and vary by procedure specifics, hospital, and clinical complexity. Request a personalised estimate for your specific case.
Faridabad, India
Asia's largest private hospital — 2,600 beds, 64 operation theatres, 81 specialties on a 130-acre campus in Delhi NCR. NABH & NABL accredited. Centres of excellence in oncology, cardiac surgery, BMT, organ transplantation, neurosciences, and IVF.
800+
Specialists
2,600+
Beds
Bengaluru, India
India's first purpose-built organ-specific oncology hospital. Ranked #1 in Bengaluru and #7 in India (Outlook Health 2025). JCI, NABH & ESMO accredited — surgical, medical and radiation oncology with dedicated BMT unit and Elekta Versa HD linac.
64+
Specialists
150+
Beds
Gurugram, India
Medanta – The Medicity is India's #1 hospital (Newsweek World's Best Hospitals 2026), founded by renowned cardiovascular surgeon Dr. Naresh Trehan on a 43-acre campus in Sector 38, Gurugram. The flagship facility operates 1,391 beds including 270+ ICU beds, 40 operating theatres, and 900+ experienced physicians across 30+ specialties. Medanta is the only Indian private hospital to be consistently ranked among the world's top 150 medical facilities, and receives over 20,000 international patients annually from more than 130 countries. Its centres of excellence span cardiac care, oncology, neurosciences, organ transplantation, gastrosciences, and orthopaedics, backed by JCI, NABH, and NABL accreditation.
900+
Specialists
1,391+
Beds
Gurugram, India
Fortis Memorial Research Institute (FMRI) in Sector 44, Gurugram is one of India's most advanced tertiary care hospitals, offering 1,000+ beds across 40+ specialties. Home to leading specialists in neurosurgery, cardiac surgery, oncology, organ transplantation, and orthopaedics, FMRI features CyberKnife radiosurgery, CAR-T cell therapy, and full robotic surgery capabilities. The hospital serves patients from 118 countries, supported by a dedicated international patients department providing visa assistance, interpreters, airport transfers, and end-to-end care coordination.
400+
Specialists
330+
Beds
Established indications include blood cancers (leukaemia, lymphoma, myeloma), bone marrow failure, sickle cell disease, and thalassaemia via HSCT. Mesenchymal stem cell therapy is used for select autoimmune and orthopaedic conditions. CAR T-cell therapy targets certain relapsed or refractory blood cancers.
No fees. No commitment.
We are compensated by our partner hospitals — never by patients. You get independent clinical matching, cost transparency, and end-to-end coordination at no cost to you.
